15 Lymphoma Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting Lymphoma Studies in Phoenix

NCT05675410Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in i...

Phoenix, AZPHASE31,875 participantsNational Cancer Institute (NCI)

View Study Details

NCT06717347Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment ...

Phoenix, AZPHASE31,046 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06549595Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared ...

Phoenix, AZPHASE31,018 participantsAstraZeneca

View Study Details

NCT05006716Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses...

Phoenix, AZPHASE1645 participantsBeiGene

View Study Details

NCT06337318Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a p...

Phoenix, AZPHASE3600 participantsNational Cancer Institute (NCI)

View Study Details

NCT06090539Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrad...

Phoenix, AZPHASE1460 participantsBristol-Myers Squibb

View Study Details

NCT01790152Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory ...

Phoenix, AZ420 participantsChildren's Oncology Group

View Study Details

NCT04792489Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractor...

Phoenix, AZPHASE2315 participantsMiltenyi Biomedicine GmbH

View Study Details

NCT06724237Recruiting

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete...

Phoenix, AZPHASE3294 participantsEastern Cooperative Oncology Group

View Study Details

NCT06526793Recruiting

AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lympho...

Phoenix, AZPHASE2270 participantsAstraZeneca

View Study Details

NCT04390737Recruiting

Evaluate the Safety and Clinical Activity of HH2853

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a ...

Phoenix, AZPHASE1254 participantsHaihe Biopharma Co., Ltd.

View Study Details

NCT03328078Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult p...

Phoenix, AZPHASE1152 participantsCuris, Inc.

View Study Details

NCT07104032Recruiting

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractor...

Phoenix, AZPHASE3132 participantsOno Pharmaceutical Co., Ltd.

View Study Details

NCT06634589Recruiting

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed...

Phoenix, AZPHASE180 participantsBeiGene

View Study Details

NCT06854003Recruiting

BRAZAN Trial in Frontline MCL

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubr...

Phoenix, AZPHASE260 participantsChristine Ryan

View Study Details

About Lymphoma Clinical Trials in Phoenix

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 15 lymphoma clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 7,621 participants. Research is being sponsored by National Cancer Institute (NCI), Merck Sharp & Dohme LLC, AstraZeneca and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Phoenix — FAQ

Are there lymphoma clinical trials in Phoenix?

Yes, there are 15 lymphoma clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 15 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 22, 2026 from ClinicalTrials.gov